Supplement 5

Interim Analysis

Table of Contents

- 5.1 Interim Analysis Report
- 5.2 Interim Efficacy Analysis Methods

Supplement 5.1: Interim Analysis Report

Device:	Vielight Rx Plus
Protocol version, date:	2.0, 19May20
Protocol title:	Treatment of Covid-19 Respiratory Symptoms.
SAP date: Interim analysis by:	12Sep20 Mark Van Buskirk, Data Reduction LLC, 472 State Route 24, Chester, NJ 07930
Interim analysis date:	25Jan21

Interim Efficacy Analysis: Sealed Results (page 1 of 2)

Sealed Results

Demography

Table 1 presents summary statistics and frequencies of demographic characteristics of Active and Control subjects. At baseline, 54.8% of patients were randomized to Active treatment and 45.2% to Control treatment. Mean age was 35.4 years (standard deviation (SD) 13.09, minimum 18, maximum 65 years). 64.4% of patients had symptom duration of 0-5 days and 35.6% of patients had symptom duration of 6-10 days. Mean response to question 1 at baseline (mean 4.6, SD 1.08) tended (p=0.063) to be greater in Active (mean 4.8, SD 0.80) than Control (mean 4.3, SD 1.31). Females were represented in 71.2% of patients and represented a statistically significantly difference (p=0.008) in Active (85.0%) than Control (54.5%).

Time to Event

Table 2 provides Kaplan-Meier estimates at the interim based on 73 completed subjects. In a model stratified by symptom duration, the median time to complete resolution of WURSS question 1 symptoms (primary efficacy endpoint) was 15.5 days (95% confidence interval (CI) (10.0, 20.0) in Active and 18.0 days (95% CI 11.0, n/a) in Control, and the p-value by a stratified log-rank test was 0.104. Subgroup analysis by symptom duration categories indicated that the greatest difference in response between treatment groups was in those with symptoms 0-5 days with median time to complete resolution of symptoms 11.0 days for Active and 14.0 days for Control, which was marginally significant (p=0.075). In patients with symptoms 6-10 days, median time to event was 21 days in Active and 22 days in Control (p=0.783).

Table 3 presents results Cox proportional hazards models, stratified by duration of symptoms (0-5 days, 6-10 days). Baseline age, gender and race did not contribute to the regression model, and the primary statistical model for the interim efficacy analysis is stratified by symptom duration with factors for treatment and baseline Q1 covariate. Results indicated that the hazard ratio was 1.72 with 95% CI (0.967, 3.060) and p-value 0.065.

A data listing of demography and derived time-to-event is provided.

Interim Efficacy Analysis: Sealed Results (page 2 of 2)

Device:	Vielight Rx Plus
Protocol version, date:	2.0, 19May20
Protocol title:	A Randomized Study Evaluating the Efficacy of the Vielight Rx Plus in the
	Treatment of Covid-19 Respiratory Symptoms.
SAP date:	12Sep20
Interim analysis by:	Mark Van Buskirk, Data Reduction LLC, 472 State Route 24, Chester, NJ 07930
Interim analysis date:	25Jan21

Interim Efficacy Analysis

At the interim efficacy analysis, the trial decision to stop the trial early for superiority was not met as the p-value for superiority by a symptom-duration stratified Cox model with baseline Q1 score covariate was p=0.065; and did not meet the established O'Brien Fleming¹ threshold for superiority of p<0.0051. The trial decision for futility was not met as the lower bound of the 95% CI for the hazard ratio (0.967) meets the criteria of conditional power >50% from Lan² equation 5.

Sample Size Re-Estimation

Sample size re-estimation by Cox regression utilizes the overall event rate (0.74) to update statistical power. Provided the event rate, protocol-stated hazard ratio (1.40) and sample size (280), the statistical power to detect a treatment difference is 68%. Power of 80% is achieved with 375 subjects. Under a fixed sample size condition of n=280 subjects, a hazard ratio of 1.58 is required to achieves 80% power to detect a treatment difference, given an overall event rate of 0.74.

¹ O/Brien PC and Fleming TR (1979). A multiple testing procedure for clinical trials. *Biometrics*. 35:549-556.
² Lan KKG and Simon R (1982). Stochastically curtailed tests in long-term clinical trials. *Communications in Statistics* Series C. 1:207-219.

Vielight Ex Plus. Protocol: Treatment of Covid-19 Respiratory Symptoms

Table 1 Interim Efficacy Analysis Baseline Characteristics

ariable	Statistic	Category	Active (N= 40)	Control (N= 33)	Total (N= 73)	P-Value^
				55	612	0.792
de (Sears)	Maan (SD)		47.EI) 0.5E	35.8 (12.40)	35.4 (13.09)	
	Made an (TOB)		33.0 (23.5)	36.0 1 19.0)	34.0 (23.0)	
	Min, Max		(18.0, 65.0)	(19.0, 63.0)	(18.0, 65.0)	
	191 0	Dore in	34 105.05	18 (54.5)	52 (71.2)	+900.0
ex.	141 10	Male	6 (15.0)	15 (45.5)	21 (28.8)	
	141 1	Cancersan	34 (85.0)	28 (84.0)	62 (84.9)	1.000
aucastan	141 0	Non-Caucastan	6 (15.0)	5 (15.2)	11 (15.1)	
	100 M	0-5 dave	24 (60.0)	23 (69.7)	47 (64.4)	0.465
whoton make	10.1	6-10 days	16 (40.0)	10 (30.3)	26 (35.6)	
and the second sec	,		40	33	13	0.512
mestion 1 at screening	Mann (en)		5.0 1 0.68)	4.9 (0.89)	4.9 1 0.781	
	Median (108)		5.0 (0.0)	5.0 (1.0)	5.0 [1.0]	
	MLn, Max		(4.0, 6.0)	1 4.0, 7.0)	(4.0, 7.0)	
and the second second second	2		40	33	73	0.063
MUTTAGEN 14 Y UNITERIA	Maan JgDA		4.8 4 0.80)	4.3 (1.31)	4.6 (1.08)	
	Madi an (T/G/		5.0 4 1.0)	4.0 (1.0)	5.0 (1.0)	
	Min. Nax		(3.0, 6.0)	(1.0, 7.0)	(1.0, 9.0)	
And the second sec	2		40	33	73	0.803
197 ON NOTIFICTION	Man 1801		0.5 (0.75)	0.5 (0.79)	0.5 (0.77)	
since and a	Modd and TOBL		0.0 0 1.01	0.0 1 1.0)	0.0 0 1.0)	
			10.0 3.01	1 0.0. 2.03	4 0.0, 3.0)	

 $^{\sim}$ p-value for continuous variables by t-test and 2x2 categorical by Fisher's Exact test.

25.3MS21, 201_damog

(abob	Treatment	Total	Failed	Canaored	Median De Months	wys to Evant	Unstratified	P-Value
Overal1	Active	40	33	5	15.5	(10.0,20.0)	0.175	0.104
	Control	EE	21	12	18.0	(11.0,		
Sumption Dave 0-5	Active	24	22	en	11.0	1 8.0,18.0)	0.075	
	Control	23	15	8	14.0	(10.0,)		
Svecton Days 6-10	Active	16	11	5	21.0	(14.0, 1	0.783	
	Control	10	w	*	22.0	(2.0,)		

Vielight Rx Flus. Protocol: Treatment of Covid-19 Baspiratory Symptoms

Overall time (days) to resolution of respiratory symptoms (MURSS Q1) is from treatment start until the event or last follow-up if no event. Median and 95% confidence interval (c.i.) from Kaplan-Meler estimation in model atratified by symptom-days (0-6,6-10).25JAN21, 702_kn_interim

Vislight RM Plus. Protocol: Treatment of Covid-19 Respiratory Symptons

	Contraction of the second seco	Proportional Mazards Model
	Ĩ	x
Table 3	Interim Efficacy Analysis	Resolution of WURSS Question 1 by C
		Complete
		\$
		71110
		Overal1

		10000		Parameter	Fatio	Lover	Upper	P-Value
t M	1ebc			Treatment	1.5817	0.9055	2.7631	0.107
3	nd Q1 Ba	seline	Covariate	Treatment Ol Baseline	1,7202	0.9670 0.6091	3.0601 1.0729	0.065

Overall time (days) to resolution of respiratory symptoms (WINSS Q1) is from treatment start until the event or last follow-up if no event p-value by symptom duration stratified Dox proportional hazards model. Nodel 2 adjusted for baseline Q1. 25JAN21, T03_cox_interim

Supplement 5.2

Interim Efficacy Analysis Methods

Interim Efficacy Analysis

Device:	Vielight Rx Plus
Protocol version, date:	2.0, 19May20
Protocol title:	A Randomized Study Evaluating the Efficacy of the Vielight Rx Plus in the
	Treatment of Covid-19 Respiratory Symptoms.
SAP date:	12Sep20
Interim analysis by:	Mark Van Buskirk, Data Reduction LLC, 472 State Route 24, Chester, NJ 07930
Interim analysis date:	26Sep20

Statistical Methods

The primary efficacy endpoint is defined as the time in days from date of first use of the device to the start date of improvement, defined as three consecutive days of reporting 0 on WURSS-44 question 1. The time to endpoint (days) is met (success) on the first of three consecutive days.

A single interim efficacy analysis was conducted on the primary efficacy endpoint in the first 73 subjects. The stopping boundary for superiority was defined as p<0.0051 by O'Brien and Fleming¹ groupsequential testing design. The stopping boundary for futility is set at conditional power²

Results from the interim efficacy analysis are reported as 'unsealed' and 'sealed' results.

Unsealed results inform:

- Stop/Continue study decision:
 Results communicated to the sponsor include the decision to either (a) stop the study for superiority, (b) stop the study for inferiority, or (c) continue the study until planned completion.
- (2) Sample size re-estimation: The statistical power of the study is addressed at the interim efficacy analysis. Statistical power analysis by Cox Proportional Hazards³ is performed using PASS software (NCSS Statistical Software, version 11.0). Sample size re-estimation uses the protocol specified hazard ratio of

¹ O'Brien PC and Fleming TR (1979). A multiple testing procedure for clinical trials. Biometrics. 35: 549-556.

² Lan KKG and Simon R (1982). Stochastically curtailed tests in long-term clinical trials. Communications in Statistics Series C. 1: 207-219.

³ Schoenfeld, David A. 1983. 'Sample-size formula for the proportional-hazards regression model', Biometrics, Volume 39, pages 499-503.

1.40 and sample size of 280 subjects and the observed event rate of 74% at the interim efficacy analysis.

<u>Sealed results</u> consist of treatment group comparisons of baseline characteristics, Kaplan-Meier time-toevent estimates, and hazard ratios and confidence intervals by Cox proportional hazards models. Statistical analysis of the primary efficacy endpoint is by Kaplan-Meier estimation, stratified by time since onset of symptoms (<=5 days, 6-10 days). Median days to improvement and 95% confidence

Interim Efficacy Analysis (page 2)

intervals are reported by treatment group. Separately by treatment group, the total number of subjects with the event (success of primary endpoint), without the event (censored), and total number of subjects are presented. For Kaplan-Meier estimation, the stratified test and univariate model by time of onset of symptoms are presented. The Cox proportional hazards model stratified by time since onset of symptoms was applied, and the hazard ratio and 95% confidence interval reported. Additionally, a stratified Cox model including covariate of baseline response to question 1 is reported.